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ABSTRACT 
Objective: To design and evaluate efficient lipid-aminoglycoside conjugates for the delivery of genes for gene therapy, and also for the delivery of 
siRNA molecules to knock down gene expression in mammalian cells 
Methods: 3β-[5”-(aminoethanethiol)-neomycin B] carbamoyl cholesterol (NeoChol) was synthesized. The abilities of this novel compound to 
condense DNA and to form nanoparticles were studied using ethidium bromide fluorescence quenching and nanoparticle characterization 
techniques. Transfection efficiency was studied in FEK4 primary skin cells and in an immortalized cancer cell line (HtTA), and compared with the 
non-liposomal transfection formulation Lipogen, N4,N9-dioleoyl-1,12-diamino-4,9-diazadodecane. Also, the abilities of this compound to condense 
siRNA and to form nanoparticles were studied using a Ribo Green intercalation assay and its abilities to deliver siRNA into cells were studied in 
FEK4 and HtTA cells using fluorescein-labelled Label IT® RNAi Delivery Control, a sequenced 21-mer from Mirus. 
Results: We show efficient pEGFP and siRNA formulation and delivery to primary skin (FEK4) and cancer cell lines (HtTA). 
Conclusion: Synthetic cationic lipid, a conjugate derived from neomycin B antibiotic and cholesterol is highly efficient for in vitro delivery of DNA 
and fluorescent siRNA. 
Keywords: ?? 
 
INTRODUCTION 
Nucleic acids show great promise as new therapeutics to treat both 
acquired and inherited diseases. One of the greatest challenges to 
the successful application of poly-nucleic acid drugs (DNA or siRNA) 
is the development of an efficacious delivery method [1]. Delivery 
systems are needed to compact genetic material into nanostructures 
that can be uptake by cells [2], to protect (poly-)nucleic acids from 
enzymatic damage during cellular transport, and to provide the 
possibility of targeting the delivery to specific cell types [3,4].  
Viral vectors are still the most effective and commonly used method 
of DNA transport even though many problems with this delivery 
method have been revealed, e.g. immunogenicity, toxicity, safety 
issues, and problems in industrial quality control and scaling-up.[5] 
Polymeric cationic vectors e.g. polyethylenimine (PEI), exhibit 
efficient gene delivery, but are also cytotoxic [6]. Conversely, 
chitosan, a polymer of glucosamine, is non-toxic yet it displays low 
gene delivery efficiency in many cell lines [7].  
Lipopolyamine-mediated gene delivery has emerged as a viable 
alternative to viral-based and polymer-based transfection systems 
[8,9], as polyamines, e.g. spermine and spermidine, are naturally 
occurring (catabolised within cells) and they have DNA-binding 
affinity, whilst inducing neither immune nor inflammatory 
responses. The synthetic gene vectors based on these polyamines 
[10,11] normally incorporate 3 parts: polyamine scaffold, 
degradable linker, and lipid unit. Several studies [10,11]have 
reported that synthetic spermine derivatives are effective gene 
delivery vectors. These polycations bind to DNA electrostatically and 
form lipoplexes (lipopolyamine and DNA complexes) that are 
endocytosed by many cell types and deliver DNA with varying 
degrees of high delivery efficiency and low (acceptable) toxicity 
[6,12].  
Cationic lipids are not only prepared from the conjugation of lipid 
moieties with linear polyamines. Lehn and co-workers [4] recently 
reported a novel use of an aminoglycoside scaffold, kanamycin, a 
polyamine on a cyclic skeleton, incorporated in a lipopolyamine 
design. Here, we report our work on the design and synthesis of a 
polyamine gene delivery vehicle based on the aminoglycoside 
neomycin B (Figure 1a) [13] that can carry up to six amino groups 
which are predominantly fully charged (protonated) at physiological 
pH [14].Consequently, we considered that this conjugate may 
condense DNA more efficiently, and may be capable of delivering 
circular plasmid DNA to hard-to-transfect primary cell lines. 
Therefore, we have synthesized 3β-[5”-(aminoethanethiol)-
neomycin B] carbamoyl cholesterol (NeoChol) (Figure 1b). 
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Fig. 1a: Neomycin B 
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Fig. 1b:  3β-[5”-(Aminoethanethiol)-neomycin B] carbamoyl 
cholesterol (hexa-trifluoroacetate salt) 
In our preliminary experiments to determine the DNA condensation 
ability across a series of readily available aminoglycosides (an 
intercalated ethidium bromide fluorescence quenching assay 
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compared with a UV λ = 320 nm light scattering assay), neomycin B 
displayed the best results. It was the most positively charged of the 
aminoglycosides we examined. Not entirely unexpectedly, however, 
free base neomycin B did not deliver pDNA encoding for enhanced 
green fluorescent protein (EGFP) in (primary) FEK4 skin cells, 
where its efficiency was only comparable with naked DNA (control, 
2 ± 2 %). This is possibly due to neomycin B’s poor solubility in the 
organic phase, and such a physicochemical property probably makes 
it impossible for this hexa-amine to traverse the lipophilic cell 
membrane. These results indicate that the efficient pDNA binding 
and condensing abilities displayed by neomycin B are not sufficient 
to bring about efficient cell transfection. So, six positive charges 
alone are not enough for transfection, a lipid unit is necessary in the 
lipopolyamine NVGT vector design. 
Our goal is to design and evaluate efficient lipid-aminoglycoside 
conjugates for the delivery of genes for gene therapy [4,14], and also 
for the delivery of siRNA molecules to knock down gene expression 
in mammalian cells [15,16]. We have therefore designed and made a 
cationic lipid based upon aminoglycoside cationic head-group linked 
to a lipid moiety e.g. cholesterol or long fatty acid chains. The 
conjugation of neomycin B via a thioether to cholesterol through a 
carbamate provides an “intelligent” material which may well 
overcome the problems still found in poly-nucleic acid delivery [17]. 
Without any pre-formation of liposomes, NeoChol brings about 
controlled self-assembly into a scaffold, based on the polycationic 
moiety, and also facilitates absorptive endocytosis and/or fusion 
with cell membranes through the lipid regions. NeoChol 
spontaneously neutralises and condenses negatively charged DNA 
and RNA, leading to the efficient nanoparticle formation after 
counterion removal in a thermodynamically favoured step. These 
bio-nanoparticles can used for siRNA delivery (using fluorescein-
tagged siRNA as the reporter). The self-assembled, non-liposomal 
complexes were characterised physicochemically by particle size 
measurement and fluorescence intercalation assay. They were 
tested, in vitro, for transfection efficiency and their cytotoxicity 
measured in the MTT assay. 
MATERIALS AND METHODS 
Materials 
Chemicals, including, reagents, solvents, buffer, and DNA were 
routinely purchased from Sigma-Aldrich, UK, except where 
indicated. Lipofectin and Lipofectamine reagents from Invitrogen 
(Life Technologies Gibco BRL) and cell cultures materials from Life 
Technologies (Paisley, Scotland). 
Synthesis of NeoChol 
For the synthesis of our target 3β-[5”-(aminoethanethiol)-neomycin 
B] carbamoyl cholesterol (NeoChol), neomycin B sulfate was 
purchased from Sigma-Aldrich (U.K.) and, without further 
purification, was converted into its free base using strongly basic 
ion-exchange resin. All six primary amine groups on neomycin B 
were N-Boc-protected in a mixed solvent system of DMF-H2O (6:1, 
v/v) according to the method of Tor et al [15]. The crude product 
was purified by column chromatographic elution over flash silica gel 
(DCM-MeOH, 20:1, v/v, 57% yield). Then, in the presence of six 
secondary alcohol functional groups, the only primary hydroxyl 
group, on the 5” position pendant from furanose ring C, was 
selectively activated using 30 eq. 2,4,6-triisopropylbenzenesulfonyl 
chloride (TPS-Cl) in pyridine at 20 oC for 16 h (monitored by DEPT 
spectroscopy, the shift of C-5” at 60.4 ppm moved significantly 
towards low field at 69.4 ppm on sulfonation). Significantly fewer 
TPS-Cl eq. were not effective in achieving a practical yield of O5”-
(2,4,6-triisopropylbenzenesulfonyl) N-hexa-tert-butyloxycarbonyl 
neomycin B. The excess of TPS-Cl was washed out with DCM in a 
column chromatographic elution over flash silica gel. The desired 
product showed Rf 0.45 by TLC with mobile phase DCM-MeOH (10:1, 
v/v). An aminoethanethiol linker to bridge between the neomycin B 
(polyamine moiety) and the lipophilic moiety (cholesteryl) was 
introduced. This linker was coupled using (freshly prepared) sodium 
ethoxide as the base. Up to 45 eq. aminoethanethiol HCl were 
converted into the free base with NaOEt and used to substitute the 
2,4,6-triisopropylbenzenesulfonate moiety. Having introduced the 
free primary amine, conjugation with cholesteryl chloroformate (1.2 
eq.) was carried out in a mixed solvent system of anhydrous THF-
DMF (3:1) and triethylamine (1.2 eq.) at 20 oC for 16 h. The product 
showed Rf 0.63 by TLC (DCM-MeOH, 10:1, v/v). A small sample, 
dissolved in DCM, was de-protected of all six Boc groups, achieved 
with TFA (6 eq.) in an ice-saline bath for 2 h with thorough stirring. 
After several co-evaporations with MeOH, the solid residue was 
dissolved in water and subsequent lyophilization afforded the 
desired product, NeoChol (TFA salt), as a fluffy white powder. 
Amplification and Purification of Plasmid DNA (pEGFP) 
We have chosen to deliver a 4.7-kbp plasmid encoding for enhanced 
green fluorescent protein (pEGFP), with a molecular weight of about 
3.1 MDa (given an average of 330 Da per nucleotide, 660 Da per base 
pair (18), carrying 9400 negative charges). DNA plasmid encoding 
enhanced green fluorescent protein (pEGFP) purchased from 
Clontech was transformed into Escherichia coli JM 109 bacterial 
strain (Promega). The transformed cells were grown in larger 
quantities of Luria-Bertani (LB) broth supplemented with 125 mg/L 
ampicillin. pEGFP plasmid was produced in large-scale using 
HiSpeed plasmid purification Maxi kit (Qiagen) according to the 
manufacturers protocol. DNA yields and purity were determined 
spectroscopically (OD260/OD280 = 1.80 to 1.90 OD, optical density) 
and by agarose gel (1% agarose) analysis. 
DNA Condensation (Ethidium Bromide Fluorescence Quenching 
Assay) 
Each concentration of the DNA stock solutions (approximately 1 
µg/µl, 1 ml) was determined spectroscopically (Milton Roy 
Spectronic 601 spectrometer, 1cm path length, 3 ml cuvette) [18] 
and 6µg (approximately 6 µl) of DNA was diluted to 3 ml with buffer 
(20 mM NaCl, 2 mM HEPES, 10 µM EDTA, pH 7.4) in a glass cuvette 
stirred with a micro-flea. Immediately prior to analysis, EthBr 
solution (3 µl, 0.5mg/ml) was added to the stirring solution and 
allowed to equilibrate for 10 min. Separately for DeChol aliquots (5 
µl, according to the ammonium/phosphate (+/–) charge ratio 
required) were then added to the stirring solution and the 
fluorescence measured after 1 min equilibration using Perkin-Elmer 
LS 50B luminescent spectrometer ( excit = 260 nm and emiss = 600 
nm with slit width 5nm) while stirring using an electronic stirrer 
(Rank Bros. Ltd.) [19, 20]. The total lipopolyamine solution added to 
the DNA solution did not exceed 5% of the total volume of the 
solution, so no correction was made for sample dilution. The 
fluorescence was expressed as the percentage of the maximum 
fluorescence when EthBr was bound to the DNA in the absence of 
competition for binding and was corrected for background 
fluorescence of free EthBr in solution. 
• RiboGreen intercalation assay 
RiboGreen solution (Invitrogen, 50 µl dil. 1 to 20) was added to each 
well of a 96-well plate containing free siRNA (50 ng) or complexed 
with NeoChol at different ratios containing in TE buffer (50 µl, 
200mM Tris-HCl, 20 mM EDTA, pH 7.5, in DEPC-treated water) using 
FLUOstar Optima Microplate Reader (BMG-LABTECH), λexcitation 480 
nm, λemission 520 nm. The amount of siRNA available to interact with 
the probe was calculated by subtracting the values of residual 
fluorescence (RiboGreen without siRNA) from those obtained for 
each measurement, and expressed as a percentage of the control 
that contained naked siRNA only, according to the following formula: 
% free siRNA = 100 x RiboGreen fluorescencecomplexes /RiboGreen 
fluorescencenaked siRNA). 
Gel Electrophoresis 
Each sample of plasmid DNA (0.5μg), either free or complexed with 
DeChol at different concentration, was analyzed by gel 
electrophoresis for about 60 min under 75 V/cm, through an 
agarose gel (1%) containing EthBr (1 μg/ml) in Tris– acetate–EDTA 
1× (40 mM Tris–acetate and 1 mM EDTA) buffer. The (unbound) free 
DNA in the agarose gel was visualized under UV using GeneGenius 
(Syngene, Cambridge, UK).  
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Lipoplex Particle Size  
The average particle size for the lipoplexes formed (at their 
optimum charge ratio of transfection), after mixing with a vortex 
mixer, was determined using a NanoSight LM10 (NanoSight Ltd, 
Salisbury, UK). All measurements were carried out on lipoplexes 
with 1μg/ml plasmid DNA in HEPES buffer at pH 7.4 in a sample 
volume 0.2ml. Results are analysed by the ground-breaking 
Nanoparticle Tracking Analysis (NTA) software. 
ζ-Potential Measurements  
The ζ−potential measurements for the lipoplexes formed (at their 
optimum charge ratio of transfection), after mixing with a vortex 
mixer, was determined using a Delsa™ Nano Zeta Potential 
(Beckman Coulter, Buckinghamshire, UK), All measurements were 
carried out on lipoplexes with 6 µg/ml plasmid DNA in HEPES buffer 
at pH 7.4 in sample volume 2ml. 
DNase I sensitivity assay 
Briefly, in a typical assay, pEGFP plasmid (1μg) was complexed with 
the varying amounts of the DeChol using the indicated charge ratios 
in a total volume of 30 μL in HEPES buffer, pH 7.40, and incubated at 
room temperature for 30 min on a rotary shaker. Subsequently, the 
complexes were treated with 10 μL DNase I (at a final concentration 
of 1 μg/mL) in presence of 20 mM MgCl2 and incubated for 20 min at 
37°C. The reactions were then halted by adding EDTA (to a final 
concentration of 50 mM) and incubated at 60° C for 10 min in a 
water bath. The aqueous layer was washed with 50 μL of 
phenol:chloroform:isoamylalcohol (25:24:1 mixture, v/v) and 
centrifuged at 10,000rpm for 5 min. The aqueous supernatants were 
seperated, loaded (15 μL) on a 1% agarose gel (pre-stained with 
ethydium bromide) and electrophoresed at 100 V for 1 h. 
Cell Culture and Transfection Experiments with pEGFP DNA  
Two cell lines were used in the transfection experiment, a human 
primary skin fibroblast cells FEK4 [20], derived from a foreskin 
explant and a human cervix carcinoma, HeLa derivative and 
transformed cell line (HtTA). The HtTA cells being stably transfected 
with a tetracycline-controlled transactivator (tTA) consisting of the 
tet repressor fused with the activating domain of virion protein 16 of 
the herpes simplex virus (HSV). Cells were cultured in Earle s 
minimal essential medium (EMEM) supplemented with foetal calf 
serum (FCS) 15% in the case of FEK4 and 10% in the case of HtTA 
cells, penicillin and streptomycin (50 IU/ml each), glutamine (2mM), 
and sodium bicarbonate (0.2%). 
For the transfection (gene delivery) and the resultant gene activity 
(transfection efficiency), FEK4 and HtTA cells were seeded at 5 × 104 
cell/well in 12 well plates in 2 ml EMEM media with FCS for 24 h to 
reach a plate confluence of 50–60% on the day of transfection, then 
replaced by 0.4ml EMEM media with FCS.The complex was prepared 
by mixing 1µg of pEGFP with the cationic lipopolyamine in Opti-
MEM according to the charge ratio at room temperature for 30 min 
and then incubated with the cells for 4 h at 37°C in 5% CO2 in full 
growth medium (in the presence of serum). Then the cells were 
washed and cultured for further 44 h in full growth medium at 37°C 
in 5% CO2 before the assay. 
Levels of enhanced green fluorescent protein (EGFP positive cells) in 
the transfected cells were detected and corrected for background 
fluorescence of the control cells using a fluorescence activated cell 
sorting (FACS) machine (Becton Dickinson FACS Vantage dual Laser 
Instrument, argon ion laser 488 nm). The transfection efficiency was 
calculated based on the percentage of the cells that expressed EGFP 
(positive cells) in the total number of cells. 
Transfection Experiments in Presence or Absence of Serum 
The same as the previous procedures but the complex added to cells 
in Earle s minimal essential medium (EMEM) (Serum free media) 
for 4 h at 37°C in 5% CO2. Then the cells were washed and cultured 
for further 44 h in full growth medium at 37°C in 5% CO2 before the 
assay. 
siRNA Transfection experiments 
We used two cell lines, a human primary skin fibroblast cell line 
(FEK4) derived from a foreskin explant cell line and a human cervix 
carcinoma, HeLa derived and transformed cell line (HtTA). For the 
transfection, FEK4 and HtTA cells were seeded at 5 × 104 cells/well 
in 12-well plates in 1 ml EMEM media with FCS for 24 h to reach a 
plate confluency of 50–60% on the day of transfection. The complex 
was prepared by mixing siRNA (12.5 pmoles) with the Transcfecting 
agent in Opti-MEM (serum free media, Gibco BRL) according to the 
optimum concentration, at 20 °C for 30 min and then incubated with 
the cells for 4 h at 37 °C in 5% CO2 using EMEM media with FCS. 
Then the cells were washed and cultured for a further 44 h in 
growth medium at 37 °C in 5% CO2 before assaying. Levels of 
fluorescence in the transfected cells were detected and corrected for 
background fluorescence of the control cells using a FACS machine 
(Becton Dickinson FACS Vantage dual Laser Instrument, argon ion 
laser 488 nm). Data were analyzed with WinMIDI (version 2.8) 
software. The transfection efficiency was calculated based on the 
percentage of the cells that expressed EGFP (positive cells) in the 
total number of cells. 
In Vitro Cytotoxicity (MTT) Assay  
FEK4 and HtTA cells were seeded in 96 well plates at 8000 cell/well 
and incubated for 24 h at 37°C in 5% CO2. Transfecting agent 
complexed with pEGFP or siRNA was added in the same way as the 
transfection protocol. After incubation for 44 h, the media was 
replaced with 90µl of fresh media and 10µl of sterile filtered MTT 
solution (Sigma-Aldrich, UK) (5 mg/ml) to reach a final 
concentration of 0.5 mg/ml. Then the plates were incubated for a 
further 4 h at 37° C in an atmosphere of 5% v/v CO2. After 
incubation, the media and the unreacted dye were aspirated and the 
formed blue formazan crystals were dissolved in 200 µl/well of 
dimethyl sulfoxide (DMSO). The produced color was measured using 
a plate-reader (VERSAmax) at wavelength 570 nm. The % viability 
related to control wells containing cells without DNA and/or 
polymer and is calculated by (test absorbance/control absorbance) 
× 100 [21]. The same protocol was applied in case of the 
commercially available reagents Lipofectin and Lipofectamine [22-
24]. 
RESULTS 
Synthesis of lipospermines 
3β-[5”-(Aminoethanethiol)-neomycin B] carbamoyl cholesterol 
(NeoChol) (6 x TFA salt) showed LSIMS HR accurate mass data: FAB+ 
m/s found 1086.6727 Da, C53H96N7O14S requires 1086.6730 [M-
6TFA+H]+, within 0.3 ppm. It was homogeneous after TFA 
deprotection of the hexa-Boc synthetic protected intermediate. 
DNA Condensation 
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Fig. 2: Plot of EthBr displacement assay of pEGFP and RiboGreen 
intercalation assay of RNA complexed with NeoChol 
Ghonaim et al. 
Int J Pharm Pharm Sci, Vol 6,Issue 2, 153-157 
156 
The EthBr displacement assay and RiboGreen intercalation assay 
shows pEGFP DNA and siRNA condensation as a function of 
increasing the N/P charge ratio (figure 2). 
The gel electrophoresis results show that all spermine conjugates 
were able to condense pEGFP DNA efficiently (as a result of 
neutralization of DNA phosphate negative charges by the 
lipopolyamines ammonium positive charges) at their optimised 
respective charge ratios (n/p) of transfection by completely 
inhibited the electrophoresis mobility of plasmid DNA. 
Lipoplex Particle Size and Zeta-Potential Measurements  
The particle size and ζ-potential characterization measurements 
were carried out on the lipoplexes at their optimum N/P charge 
ratio of transfection. Particle size characterization by laser 
diffraction showed that the average particle size of. The surface 
charge, as determined by ζ-potential measurements. -Potential is an 
important parameter helping to predict the stability of the 
formulation as well as the ability of the positively charged particles 
to interact with cell membranes. ζ-Potential depends on several 
factors, including pH, ionic charge, ion size, and concentration of ions 
in solution. The formed nanoparticles are considered to be stable 
when they have pronounced ζ-potential values, either positive or 
negative, but the tendency to aggregate is higher when the ζ-
potential is close to zero the measured zeta potential for the naked 
DNA is -1.02 and +18.05 for condensed DNA at optimum N/P ratio. 
For the nanoparticles, the average particle size was 200 nm for 
pDNA and 120 nm for siRNA Nase I Protection 
The DNase I protection experiment carried using plasmid DNA 
complexed with the different N/P ratios lipopolyamines. Reasonably 
intense undigested DNA bands were detected in the gel as a control 
and no band for uncondensed DNA which digested by DNase I as 
negative control. We performed the DNase protection experiment 
using different N/P ratios of DeChol which mean that DNA 
condensed with these lipopolyamines completely protected from 
DNase I enzyme (figure 3).  
 
Fig. 3: Gel electrophoresis assay of pEGFP complexed with 
NeoChol at different N/P ratios 
Transfection Experiments and In Vitro Cytotoxicity 
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Fig. 4: Lipofection of FEK4 cell lines transfected with DNA 
complexed with neomycin B and NeoChol at different N/P 
charge ratios 
Fig. 4:  shows that neomycin B did not transfect the FEK4 primary 
cell line (although it did condense pDNA). However, NeoChol, as a 
function of increasing N/P charge ratio showed efficient DNA 
transfection was achieved at N/P 10 and 12. 
Fig. 4:  show efficient transfection efficiency of NeoChol even in 
presence of serum. Figures 5 and 6 show efficient NeoChol 
transfection with good viability comparable to the commercial 
transfecting agent LipoGen for DNA delivery and TransIT for siRNA 
delivery 
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Fig. 5: Lipofection of FEK4 and HtTA cell lines transfected with 
DNA complexed with NeoChol in presence and absence of 
serum. 
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Fig. 6: Lipofection and viability of FEK4 and HtTA cell lines 
transfected with DNA complexed with NeoChol 
The gene delivery efficiency and cell viability of NeoChol were 
examined with an FEK4 cell line (primary skin fibroblast, derived 
from a foreskin explant). As positive controls for these experiments, 
we compared the delivery efficiency and toxicity of our conjugate 
with N4, N9-dioleoyl spermine (Lipogen) that is an established gene 
delivery agent.10 Untransfected cells, “naked” pDNA, and the parent 
drug, neomycin B, were used as the negative controls in these 
experiments. The transfection efficiency was calculated based on the 
percentage of cells that expressed EGFP (positive cells) in the total 
number of cells (Figure 4). Under the same conditions when 
neomycin B did not show any (2 ± 2 %) cell transfection ability, 
using the same FEK4 primary skin cell line, NeoChol showed 82 ± 3 
% transfection (n = 9) at ammonium/phosphate (N/P) charge ratio 
10 (Figure 4). An acceptable level of cell toxicity was established in 
an MTT assay, showing 58.2 ± 3.8 % cells survival. The results from 
this transfection assay indicate that a combined consequence of the 
good pDNA binding and condensing affinity displayed by the 
neomycin B moiety and the lipophilic property of the cholesteryl 
unit is efficient primary cell line transfection, when compared to the 
parent molecule, neomycin B or to naked DNA (Figure 4). 
Furthermore, NeoChol (at N/P charge ratios 10-12) is at least as 
efficient as commercially available Lipogen (Figure 6). 
siRNA Transfection  
Figure 7 shows efficient siRNA delivery and cell viability as good as 
the commercial compound Trans IT for both primary FEK4 and 
Cancer HtTA cell lines  
In summary, novel therapeutic poly-nucleic acids may yield 
revolutionary advances in modern medicine, provided that a safe 
and effective delivery method is discovered. Here, we report the 
synthesis and biological activity of NeoChol that exhibits high gene 
delivery efficiency with low toxicity in a cancer cell line and primary 
skin cell line as good as the commercially available Lipogen, and 
comparable with TransIT-TKO® for siRNA delivery. 
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Fig. 7: Delivery and viability of FEK4 and HtTA cell lines 
transfected with fluorescent siRNA complexed with NeoChol 
CONCLUSIONS 
We have demonstrated that a synthetic cationic lipid, a conjugate 
derived from neomycin B antibiotic and cholesterol is highly 
efficient for the in vitro delivery of DNA (65-80%) and fluorescent 
siRNA (85-90%). Good cell viability was also observed compared 
with TransIT (for RNA) (80-95%) and LipoGen (for DNA) (60-85%) 
delivery. NeoChol is a candidate medicine worthy of further 
development due to its efficient gene and siRNA delivery with low 
toxicity. It is a novel, efficient non-viral vector in the presence of 
serum. 
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